Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005

Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance

David J. Farrell*Comments to Author , Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
Author affiliations: *G.R. Micro Ltd, London, United Kingdom; †Mount Sinai School of Medicine, New York, New York, USA; ‡Clinical Microbiology Institute, Wilsonville, Oregon, USA; §sanofi-aventis, Bridgewater, New Jersey, USA; ¶Emory University, Atlanta, Georgia, USA; #University of the Witwatersrand, Johannesburg, South Africa

Main Article

Table 4

Susceptibility to various antibacterial drugs among Streptococcus pneumoniae isolates collected from years 1–3 of the PROTEKT US study that had both erm(B) and mef(A) macrolide resistance genes (n = 1,159)

Drug % susceptibility*
Susceptible Intermediate Resistant
Amoxicillin–clavulanate† 40.6 22.0 37.4
Azithromycin 0 0.1 99.9
Cefuroxime 5.7 1.7 92.6
Clarithromycin 0 0 100
Co-trimoxazole 3.4 1.2 95.4
Erythromycin 0 0 100
Levofloxacin 98.6 0 1.4
Linezolid 99.8 0 0.2
Penicillin 1.5 6.7 91.8
Telithromycin 99.0 0.9 0.1
Tetracycline 2.7 0.7 96.6

*Susceptibility was defined according to Clinical and Laboratory Standards Institute interpretive criteria (25).
†Amoxicillin alone was not tested; however, susceptibility can be extrapolated from the amoxicillin-clavulanate results.

Main Article

  1. Hoberman  A, Marchant  CD, Kaplan  SL, Feldman  S. Treatment of acute otitis media. Consensus recommendations. Clin Pediatr. 2002;41:37390. DOIPubMedGoogle Scholar
  2. Niederman  MS, Mandell  LA, Anzueto  A, Bass  JB, Broughton  WA, Campbell  GD, ; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:173054.PubMedGoogle Scholar
  3. Ball  P. Epidemiology of chronic bronchitis and its exacerbations. Chest. 1995;108(Suppl):43S52S. DOIPubMedGoogle Scholar
  4. Anon  JB, Jacobs  MR, Poole  MD, Ambrose  PG, Benninger  MS, Hadley  JA, Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130(Suppl):145.PubMedGoogle Scholar
  5. Doern  GV, Pfaller  MA, Kugler  K, Freeman  J, Jones  RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998;27:76470. DOIPubMedGoogle Scholar
  6. Doern  GV, Heilmann  KP, Huynh  HK, Rhomberg  PR, Coffman  SL, Brueggemann  AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother. 2001;45:17219. DOIPubMedGoogle Scholar
  7. Hoban  D, Waites  K, Felmingham  D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999–2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis. 2003;45:2519. DOIPubMedGoogle Scholar
  8. Karlowsky  JA, Thornsberry  C, Critchley  IA, Jones  ME, Evangelista  AT, Noel  GJ, Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000–2001 and 2001–2002 TRUST studies in the United States. Antimicrob Agents Chemother. 2003;47:17907. DOIPubMedGoogle Scholar
  9. Doern  GV, Brown  SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–2001. J Infect. 2004;48:5665. DOIPubMedGoogle Scholar
  10. Whitney  CG, Farley  MM, Hadler  J, Harrison  LH, Lexau  C, Reingold  A, Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:191724. DOIPubMedGoogle Scholar
  11. Felmingham  D, Grüneberg  RN. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000;45:191203. DOIPubMedGoogle Scholar
  12. Hoban  DJ, Doern  GV, Fluit  AC, Roussel-Delvallez  M, Jones  RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis. 2001;32(Suppl 2):S8193. DOIPubMedGoogle Scholar
  13. Felmingham  D, Reinert  RR, Hirakata  Y, Rodloff  A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002;50(Suppl 2):2537. DOIPubMedGoogle Scholar
  14. Farrell  DJ, Morrissey  I, Bakker  S, Felmingham  D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999–2000 study. J Antimicrob Chemother. 2002;50(Suppl 2):3947. DOIPubMedGoogle Scholar
  15. Farrell  DJ, Morrissey  I, Bakker  S, Morris  L, Buckridge  S, Felmingham  D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B) and mef(A)-mediated macrolide resistance. J Clin Microbiol. 2004;42:7648. DOIPubMedGoogle Scholar
  16. Leclercq  R, Courvalin  P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother. 1991;35:126772.PubMedGoogle Scholar
  17. Sutcliffe  J. Resistance to macrolides mediated by efflux mechanism. Curr Opin Anti-Infect Investig Drugs. 1999;1:40312.
  18. Corso  A, Severina  EP, Petruk  VF, Mauritz  TR, Tomasz  A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist. 1998;4:32537. DOIPubMedGoogle Scholar
  19. McGee  L, Klugman  KP, Wasas  A, Capper  T, Brink  A; Antibiotic Surveillance Forum of South Africa. Serotype 19F multiresistant pneumococcal clone harboring two erythromycin resistance determinants [erm(B) and mef(A)] in South Africa. Antimicrob Agents Chemother. 2001;45:15958. DOIPubMedGoogle Scholar
  20. McGee  L, Wang  H, Wasas  A, Huebner  R, Chen  M, Klugman  KP. Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones. Microb Drug Resist. 2001;7:5563. DOIPubMedGoogle Scholar
  21. Waites  KB, Jones  KE, Kim  KH, Moser  SA, Johnson  CN, Hollingshead  SK, Dissemination of macrolide-resistant Streptococcus pneumoniae isolates containing both erm(B) and mef(A) in South Korea. J Clin Microbiol. 2003;41:578791. DOIPubMedGoogle Scholar
  22. Ko  KS, Song  JH. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes. J Infect Dis. 2004;190:73947. DOIPubMedGoogle Scholar
  23. Felmingham  D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother. 2002;50(Suppl 2):17. DOIPubMedGoogle Scholar
  24. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M07‑A6. Wayne (PA): The Institute; 2003.
  25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. Document M100-S15. Wayne (PA): The Institute; 2005.
  26. Farrell  DJ, Morrissey  I, Bakker  S, Felmingham  D. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J Antimicrob Chemother. 2001;48:5414. DOIPubMedGoogle Scholar
  27. Shackcloth  J, Williams  L, Farrell  DJ. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromycin versus comparators. J Infect. 2004;48:22935. DOIPubMedGoogle Scholar
  28. Jolley  KA, Feil  EJ, Chan  MS, Maiden  MC. Sequence type analysis and recombinational tests (START). Bioinformatics. 2001;17:12301. DOIPubMedGoogle Scholar
  29. Pneumococcal Molecular Epidemiology Network [homepage on the Internet]. [cited 2004 Nov 22]. Available from
  30. Garau  J. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg? Respir Med. 2001;95(Suppl A):S511. DOIPubMedGoogle Scholar
  31. Lonks  JR. What is the clinical impact of macrolide resistance? Curr Infect Dis Rep. 2004;6:712. DOIPubMedGoogle Scholar
  32. Richter  SS, Heilmann  KP, Coffman  SL, Huynh  HK, Brueggemann  AB, Pfaller  MA, The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994–2000. Clin Infect Dis. 2002;34:3309. DOIPubMedGoogle Scholar
  33. Bean  DC, Klena  JD. Prevalence of erm(A) and mef(B) erythromycin resistance determinants in isolates of Streptococcus pneumoniae from New Zealand. J Antimicrob Chemother. 2002;50:5979. DOIPubMedGoogle Scholar
  34. Weiss  K, Guilbault  C, Cortes  L, Restieri  C, Low  DE; EQUERE Project. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin. J Antimicrob Chemother. 2002;50:4036. DOIPubMedGoogle Scholar
  35. Montanari  MP, Mingoia  M, Cochetti  I, Varaldo  PE. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Microbiol. 2003;41:42831. DOIPubMedGoogle Scholar
  36. Amezaga  MR, Carter  PE, Cash  P, McKenzie  H. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol. 2002;40:33138. DOIPubMedGoogle Scholar
  37. Kaplan  SL, Mason  EO Jr, Wald  ER, Schutze  GE, Bradley  JS, Tan  TQ, Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:4439. DOIPubMedGoogle Scholar
  38. Black  S, Shinefield  H, Baxter  R, Austrian  R, Bracken  L, Hansen  J, Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:4859. DOIPubMedGoogle Scholar
  39. Eskola  J, Kilpi  T, Palmu  A, Jokinen  J, Haapakoski  J, Herva  E, Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:4039. DOIPubMedGoogle Scholar
  40. Ekström  N, Åhman  H, Verho  J, Jokinen  J, Väkeväinen  M, Kilpi  T, Kinetics and avidity of antibodies evoked by heptavalent pneumococcal vaccines PncCRM and PncOMPC in the Finnish otitis media vaccine trial. Infect Immun. 2005;73:36977. DOIPubMedGoogle Scholar

Main Article

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.